Novo seeks a cardiovascular boost

Data from Mounjaro’s pivotal trial in obesity, released in April, make Lilly’s incretin look better than its forerunner, Novo Nordisk’s Wegovy, once again. But a readout is coming that could provide a massive boost for Novo’s product.

Select, the vast trial assessing Wegovy’s effect on cardiovascular outcomes among patients with obesity, is expected to yield data this summer. A hit could provide even more reason for doctors to prescribe the therapy – though with Novo already struggling to meet demand, it could be some time before the Danish group sees the effects.